90%Confidence
0Views
FDASource
2026-04-20Date
Summary
The recall of a 100 mL saline bag further confirms persistent sterility assurance problems at Fresenius Kabi. This could trigger contract losses with healthcare providers and distributors like BD.
Actionable: Investigate the potential ripple effects on BD and other partners in the pharmaceutical supply chain.
AI Confidence: 90%
Data Points
firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.9% Sodium Chloride Injection, USP, 0.9% (900 mg per 100 mL) (9 mg per mL) 100 mL in a 100 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresen
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now